CeriBell (NASDAQ:CBLL) VP Sells 9,255 Shares of Stock

Key Points

• CeriBell VP David Foehr sold 9,255 shares at an average $24.25, generating $224,433.75 and reducing his position by 21.33% to 34,144 shares.
• CeriBell shares fell 4.0% to $23.43, while the company’s latest quarterly results missed EPS expectations despite revenue exceeding estimates; analysts project a full-year loss of $1.96 per share.
• Analyst sentiment remains cautiously positive, with a consensus “Moderate Buy” rating and a $24.40 target price, although ratings range from “Strong Buy” to “Sell.”

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 9,255 shares of CeriBell stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total transaction of $224,433.75. Following the completion of the transaction, the vice president owned 34,144 shares of the company's stock, valued at $827,992. This trade represents a 21.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total value of $20,573.05.
• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total value of $23,851.86.

CeriBell Stock Down 4.0%

Shares of CeriBell stock traded down $0.98 on Thursday, reaching $23.43. 220,126 shares of the company were exchanged, compared to its average volume of 327,873. CeriBell, Inc. has a 1-year low of $10.85 and a 1-year high of $25.33. The company has a market cap of $899.24 million, a P/E ratio of -13.31 and a beta of 0.95. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. The stock's 50 day moving average price is $21.03 and its 200-day moving average price is $19.61.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million for the quarter, compared to analyst estimates of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, equities analysts forecast that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analysts Forecast Growth

CBLL has been the subject of several research analyst reports. Raymond James Financial reaffirmed a "strong-buy" rating and set a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. BTIG Research boosted their price objective on shares of CeriBell from $28.00 to $30.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Barclays upgraded CeriBell to a "neutral" rating in a report on Tuesday, August 18th. Canaccord Genuity Group lifted their target price on CeriBell from $25.00 to $26.00 and gave the company a "buy" rating in a report on Tuesday, August 11th. Finally, Weiss Ratings downgraded CeriBell from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio purchased a new stake in shares of CeriBell in the first quarter worth about $27,000. Caitong International Asset Management Co. Ltd grew its position in CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company's stock valued at $28,000 after acquiring an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of CeriBell during the third quarter valued at approximately $33,000. Tower Research Capital LLC TRC lifted its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in shares of CeriBell during the second quarter worth $53,000.

CeriBell Company Profile

CeriBell Corp NASDAQ: CBLL is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.